TCGA-FD-A3SR-01A-11R-A22U-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 19.77660972
- os_event
- true
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.490
- PROTEIN_SECRETION+0.350
- INTERFERON_GAMMA_RESPONSE+0.320
- UNFOLDED_PROTEIN_RESPONSE+0.300
- MITOTIC_SPINDLE+0.280
- UV_RESPONSE_DN+0.210
- PI3K_AKT_MTOR_SIGNALING+0.180
- HEME_METABOLISM+0.170
- CHOLESTEROL_HOMEOSTASIS+0.150
- DNA_REPAIR+0.070
Top 10 suppressed
- ANGIOGENESIS-0.400
- HYPOXIA-0.350
- OXIDATIVE_PHOSPHORYLATION-0.350
- TNFA_SIGNALING_VIA_NFKB-0.330
- MYC_TARGETS_V2-0.270
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.270
- XENOBIOTIC_METABOLISM-0.270
- KRAS_SIGNALING_DN-0.230
- ESTROGEN_RESPONSE_LATE-0.220
- FATTY_ACID_METABOLISM-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8942972 | — | — | 0.732 |
| 2 | TCGA-D8-A140-01A-11R-A115-07 | — | B | 0.700 |
| 3 | MNG59 | — | — | 0.697 |
| 4 | MDT-AP-3309 | Med | Medulloblastoma | 0.696 |
| 5 | TCGA-A7-A26J-01A-11R-A169-07 | — | B | 0.685 |
| 6 | SRR9879266 | — | cohortMD2 | 0.684 |
| 7 | MNG1006 | — | — | 0.683 |
| 8 | MNG269 | — | — | 0.683 |
| 9 | TCGA-S3-A6ZF-01A-32R-A32P-07 | — | B | 0.683 |
| 10 | 6b375859-116e-4a5e-b5b4-994a56cc9a75 | — | — | 0.682 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.490 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.350 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.320 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.300 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.280 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.210 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.180 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.170 | Temsirolimus | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.150 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.070 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.050 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.040 | Inavolisib | — uncovered |
| COMPLEMENT | 0.030 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.020 | Inavolisib | — uncovered |